(Reuters) - Johnson & Johnson (JNJ.N) on Tuesday reported quarterly profit above estimates and raised its full-year forecast, as demand for its cancer drugs Zytiga and Imbruvica helped offset decline in sales of blockbuster drug, Remicade. REUTERS/Thomas White J&J said it now expects adjusted 2018 earnings per share to be in the range of $8.13 and $8.18, up from its previous range of $8.07 to $8.17.